{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:32:04Z","timestamp":1760189524449},"reference-count":73,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bprch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.beha.2016.08.023","type":"journal-article","created":{"date-parts":[[2016,10,8]],"date-time":"2016-10-08T11:07:54Z","timestamp":1475924874000},"page":"194-205","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Current therapy guidelines for Waldenstrom's macroglobulinaemia"],"prefix":"10.1016","volume":"29","author":[{"given":"Efstathios","family":"Kastritis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.beha.2016.08.023_bib1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization (WHO) classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2016.08.023_bib2","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/sonc.2003.50082","article-title":"Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's macroglobulinemia","volume":"30","author":"Owen","year":"2003","journal-title":"Semin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2016.08.023_bib3","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1053\/sonc.2003.50038","article-title":"Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's macroglobulinemia","volume":"30","author":"Kyle","year":"2003","journal-title":"Semin Oncol"},{"issue":"9","key":"10.1016\/j.beha.2016.08.023_bib4","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1182\/blood-2005-02-0833","article-title":"Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia","volume":"107","author":"Treon","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2016.08.023_bib5","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1200\/JCO.2008.17.7865","article-title":"Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's macroglobulinemia","volume":"27","author":"Dimopoulos","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.beha.2016.08.023_bib6","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1182\/blood-2014-03-565135","article-title":"Treatment recommendations for patients with Waldenstrom macroglobulinemia (WM) and related disorders: IWWM-7 consensus","volume":"124","author":"Dimopoulos","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2016.08.023_bib7","first-page":"54","article-title":"Guideline for diagnosis and treatment of Waldenstrom's macroglobulinaemia","volume":"71","author":"Vos","year":"2013","journal-title":"Neth J Med"},{"issue":"9","key":"10.1016\/j.beha.2016.08.023_bib8","doi-asserted-by":"crossref","first-page":"824","DOI":"10.4065\/mcp.2010.0304","article-title":"Diagnosis and management of Waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines","volume":"85","author":"Ansell","year":"2010","journal-title":"Mayo Clin Proc."},{"issue":"3","key":"10.1016\/j.beha.2016.08.023_bib9","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/bjh.12760","article-title":"Guidelines on the diagnosis and management of Waldenstrom macroglobulinaemia","volume":"165","author":"Owen","year":"2014","journal-title":"Br J Haematol"},{"issue":"Suppl. 6","key":"10.1016\/j.beha.2016.08.023_bib10","doi-asserted-by":"crossref","first-page":"vi155","DOI":"10.1093\/annonc\/mdt298","article-title":"Waldenstrom's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Buske","year":"2013","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.beha.2016.08.023_bib11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/bjh.12102","article-title":"Response assessment in Waldenstrom macroglobulinaemia: update from the VIth International Workshop","volume":"160","author":"Owen","year":"2013","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.beha.2016.08.023_bib12","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1002\/cncr.20658","article-title":"Initial immunoglobulin M \u2018flare\u2019 after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study","volume":"101","author":"Ghobrial","year":"2004","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.beha.2016.08.023_bib13","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2009-05-174359","article-title":"How I treat Waldenstrom macroglobulinemia","volume":"114","author":"Treon","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2016.08.023_bib14","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/annonc\/mdh403","article-title":"Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia","volume":"15","author":"Treon","year":"2004","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.beha.2016.08.023_bib15","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1158\/1078-0432.CCR-06-2511","article-title":"Multicenter clinical trial of bortezomib in relapsed\/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248","volume":"13","author":"Treon","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.beha.2016.08.023_bib16","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2005.04.6789","article-title":"Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity","volume":"24","author":"Strauss","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2016.08.023_bib17","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.2951.2951","article-title":"Prospective, multicenter study of the mTOR inhibitor everolimus (RAD001) as primary therapy in Waldenstrom\u2019s macroglobulinemia [Abstract]","author":"Treon","year":"2011","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.beha.2016.08.023_bib18","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1182\/blood.V122.21.1822.1822","article-title":"Prospective, multicenter study of the MTOR inhibitor everolimus (RAD001) as primary therapy in Waldenstrom\u2019s macroglobulinemia","volume":"122","author":"Tripsas","year":"2013","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.beha.2016.08.023_bib19","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstrom's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.beha.2016.08.023_bib20","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1182\/blood-2015-01-553974","article-title":"How I treat Waldenstrom macroglobulinemia","volume":"126","author":"Treon","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2016.08.023_bib21","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.clml.2013.02.013","article-title":"Role of plasmapheresis in Waldenstrom's macroglobulinemia","volume":"13","author":"Stone","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"10.1016\/j.beha.2016.08.023_bib22","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1200\/JCO.2002.09.039","article-title":"Treatment of Waldenstrom's macroglobulinemia with rituximab","volume":"20","author":"Dimopoulos","year":"2002","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2016.08.023_bib23","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1080\/10428190410001723287","article-title":"Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progression","volume":"45","author":"Dimopoulos","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.beha.2016.08.023_bib24","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3816\/CLM.2005.n.014","article-title":"Predictive factors for response to rituximab in Waldenstrom's macroglobulinemia","volume":"5","author":"Dimopoulos","year":"2005","journal-title":"Clin Lymphoma"},{"issue":"1","key":"10.1016\/j.beha.2016.08.023_bib25","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/annonc\/mdi022","article-title":"Extended rituximab therapy in Waldenstrom's macroglobulinemia","volume":"16","author":"Treon","year":"2005","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.beha.2016.08.023_bib26","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/00002371-200105000-00012","article-title":"CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia","volume":"24","author":"Treon","year":"2001","journal-title":"J Immunother"},{"issue":"10","key":"10.1016\/j.beha.2016.08.023_bib27","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1080\/10428190410001714043","article-title":"Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98)","volume":"45","author":"Gertz","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.beha.2016.08.023_bib28","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3816\/CLM.2002.n.022","article-title":"Extended rituximab therapy for previously untreated patients with Waldenstrom's macroglobulinemia","volume":"3","author":"Dimopoulos","year":"2002","journal-title":"Clin Lymphoma"},{"issue":"1","key":"10.1016\/j.beha.2016.08.023_bib29","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1200\/JCO.2005.04.6474","article-title":"Flare in neuropathy following rituximab therapy for Waldenstrom's macroglobulinemia","volume":"24","author":"Noronha","year":"2006","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.beha.2016.08.023_bib30","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2013-05-503862","article-title":"Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)","volume":"122","author":"Dimopoulos","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2016.08.023_bib31","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1586\/ehm.11.62","article-title":"Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms","volume":"4","author":"Tesfa","year":"2011","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"10.1016\/j.beha.2016.08.023_bib32","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1200\/JCO.2005.06.059","article-title":"Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia","volume":"23","author":"Treon","year":"2005","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2016.08.023_bib33","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/ajh.21818","article-title":"Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcgammaRIIIa 158(V\/F) polymorphism","volume":"85","author":"Li","year":"2010","journal-title":"Am J Hematol"},{"issue":"21","key":"10.1016\/j.beha.2016.08.023_bib34","first-page":"1795","article-title":"A phase II trial of ofatumumab in subjects with Waldenstrom's macroglobulinemia","volume":"116","author":"Furman","year":"2010","journal-title":"ASH Annu Meet Abstr"},{"issue":"21","key":"10.1016\/j.beha.2016.08.023_bib35","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1182\/blood.V124.21.2610.2610","article-title":"Clinical characteristics of rituximab intolerance in patients with Waldenstrom's macroglobulinemia","volume":"124","author":"Kanan","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2016.08.023_bib36","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1182\/blood-2007-09-115170","article-title":"Targeting NF-kappaB in Waldenstrom macroglobulinemia","volume":"111","author":"Leleu","year":"2008","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2016.08.023_bib37","doi-asserted-by":"crossref","first-page":"4752","DOI":"10.1182\/blood-2007-11-120972","article-title":"Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia","volume":"111","author":"Roccaro","year":"2008","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2016.08.023_bib38","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1158\/1078-0432.CCR-10-2130","article-title":"Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's macroglobulinemia","volume":"17","author":"Sacco","year":"2011","journal-title":"Clin Cancer Res."},{"issue":"12","key":"10.1016\/j.beha.2016.08.023_bib39","first-page":"1655","article-title":"Treatment of relapsed or refractory Waldenstrom's macroglobulinemia with bortezomib","volume":"90","author":"Dimopoulos","year":"2005","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.beha.2016.08.023_bib40","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1200\/JCO.2006.07.8659","article-title":"Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Chen","year":"2007","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.beha.2016.08.023_bib41","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial","volume":"28","author":"Palumbo","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.beha.2016.08.023_bib42","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1200\/JCO.2009.25.3237","article-title":"Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia","volume":"28","author":"Ghobrial","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2016.08.023_bib43","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1200\/JCO.2012.41.6180","article-title":"Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma","volume":"31","author":"San Miguel","year":"2013","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.beha.2016.08.023_bib44","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1182\/blood.V122.21.757.757","article-title":"Carfilzomib, rituximab and dexamethasone (CaRD) is highly active and offers a neuropathy sparing approach for proteasome-inhibitor based therapy in Waldenstrom\u2019s macroglobulinemia","volume":"122","author":"Tripsas","year":"2013","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.beha.2016.08.023_bib45","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood.V124.21.1715.1715","article-title":"Updated results from a multicenter, open-label, dose-escalation phase 1b\/2 study of single-agent oprozomib in patients with Waldenstr\u00f6m macroglobulinemia (WM)","volume":"124","author":"Siegel","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2016.08.023_bib46","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1200\/JCO.2012.44.7920","article-title":"Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenstrom macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma","volume":"31","author":"Leblond","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2016.08.023_bib47","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3816\/CLML.2011.n.030","article-title":"Bendamustine therapy in patients with relapsed or refractory Waldenstrom's macroglobulinemia","volume":"11","author":"Treon","year":"2011","journal-title":"Clin lymphoma myeloma leuk"},{"issue":"9","key":"10.1016\/j.beha.2016.08.023_bib48","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.beha.2016.08.023_bib49","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood.V126.23.2745.2745","article-title":"Ibrutinib therapy in rituximab-refractory patients with Waldenstr\u00f6m's macroglobulinemia: initial results from an international, multicenter, open-label phase 3 substudy (iNNOVATE\u2122)","volume":"126","author":"Dimopoulos","year":"2015","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.beha.2016.08.023_bib50","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1182\/blood-2014-06-583294","article-title":"Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions","volume":"124","author":"Levade","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2016.08.023_bib51","doi-asserted-by":"crossref","first-page":"E312","DOI":"10.1002\/ajh.24366","article-title":"Atrial fibrillation associated with Ibrutinib in Waldenstrom's macroglobulinemia","volume":"91","author":"Gustine","year":"2016","journal-title":"Am J Hematol"},{"issue":"25","key":"10.1016\/j.beha.2016.08.023_bib52","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","article-title":"Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling","volume":"124","author":"McMullen","year":"2014","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.beha.2016.08.023_bib53","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1200\/JCO.2001.19.16.3596","article-title":"Treatment of Waldenstrom's macroglobulinemia with thalidomide","volume":"19","author":"Dimopoulos","year":"2001","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2016.08.023_bib54","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1053\/sonc.2003.50079","article-title":"Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone","volume":"30","author":"Dimopoulos","year":"2003","journal-title":"Semin Oncol"},{"issue":"21","key":"10.1016\/j.beha.2016.08.023_bib55","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1182\/blood.V124.21.4478.4478","article-title":"Lenalidomide is safe and active in Waldenstrom macroglobulinemia (WM)","volume":"124","author":"Leleu","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2016.08.023_bib56","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/ajh.23620","article-title":"Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom macroglobulinemia","volume":"89","author":"Ghobrial","year":"2014","journal-title":"Am J Hematol"},{"issue":"22","key":"10.1016\/j.beha.2016.08.023_bib57","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1200\/JCO.2007.10.9926","article-title":"Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide","volume":"25","author":"Dimopoulos","year":"2007","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.beha.2016.08.023_bib58","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/blood-2015-05-647420","article-title":"Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia: final analysis of a phase 2 study","volume":"126","author":"Kastritis","year":"2015","journal-title":"Blood"},{"issue":"9873","key":"10.1016\/j.beha.2016.08.023_bib59","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.beha.2016.08.023_bib60","first-page":"2739","volume":"120","author":"Rummel","year":"2012","journal-title":"ASH Annu Meet Abstr"},{"issue":"9","key":"10.1016\/j.beha.2016.08.023_bib61","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.3109\/10428194.2015.1012714","article-title":"Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenstrom macroglobulinemia","volume":"56","author":"Tedeschi","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2016.08.023_bib62","first-page":"1","article-title":"Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenstrom macroglobulinemia","author":"Tedeschi","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"16","key":"10.1016\/j.beha.2016.08.023_bib63","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1182\/blood-2008-09-177329","article-title":"Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia","volume":"113","author":"Treon","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2016.08.023_bib64","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/cncr.26303","article-title":"Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease","volume":"118","author":"Tedeschi","year":"2012","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.beha.2016.08.023_bib65","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1200\/JCO.2007.15.1530","article-title":"Increased incidence of transformation and myelodysplasia\/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs","volume":"27","author":"Leleu","year":"2009","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.beha.2016.08.023_bib66","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1200\/JCO.2008.20.4677","article-title":"Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180","volume":"27","author":"Treon","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.beha.2016.08.023_bib67","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/ajh.21788","article-title":"Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom macroglobulinemia","volume":"85","author":"Ghobrial","year":"2010","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.beha.2016.08.023_bib68","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/blood-2014-03-566273","article-title":"Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom's macroglobulinemia","volume":"124","author":"Treon","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2016.08.023_bib69","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1182\/blood-2008-04-150854","article-title":"Thalidomide and rituximab in Waldenstrom macroglobulinemia","volume":"112","author":"Treon","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2016.08.023_bib70","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1158\/1078-0432.CCR-08-0862","article-title":"Lenalidomide and rituximab in Waldenstrom's macroglobulinemia","volume":"15","author":"Treon","year":"2009","journal-title":"Clin Cancer Res."},{"issue":"3","key":"10.1016\/j.beha.2016.08.023_bib71","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1365-2141.2011.08750.x","article-title":"Maintenance rituximab is associated with improved clinical outcome in rituximab naive patients with Waldenstrom macroglobulinaemia who respond to a rituximab-containing regimen","volume":"154","author":"Treon","year":"2011","journal-title":"Br J Haematol"},{"issue":"s2","key":"10.1016\/j.beha.2016.08.023_bib72","article-title":"Allogeneic stem cell transplantation (ALLO-SCT) in Waldenstrom macroglobulinemia (WM). An analysis of 106 cases from the European Bone Marrow Registry (EBMT)","volume":"92","author":"Kyriakou","year":"2007","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.beha.2016.08.023_bib73","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.3324\/haematol.2015.124149","article-title":"Competing risk survival analysis in patients with symptomatic Waldenstrom macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy","volume":"100","author":"Kastritis","year":"2015","journal-title":"Haematologica"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692616300500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692616300500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T13:59:13Z","timestamp":1601128753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692616300500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S1521692616300500"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2016.08.023","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current therapy guidelines for Waldenstrom's macroglobulinaemia","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2016.08.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}